GHRP-6
Also known as: GHRP-6
An early growth hormone releasing peptide best known for strong GH stimulation alongside a pronounced increase in appetite via ghrelin signaling.
Last updated
Mechanism of Action
GHRP-6 is a synthetic hexapeptide that activates the ghrelin receptor (GHS-R1a), prompting the pituitary to release growth hormone. Because it strongly mimics ghrelin, it produces a marked increase in hunger, making it of interest where appetite stimulation is desirable. At higher doses it can also elevate cortisol and prolactin, and it works synergistically with GHRH analogs.
- Half-life
- Approximately 15-60 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Robust GH release
- Strong appetite stimulation (useful in research on cachexia/under-eating)
- Supports recovery and lean mass
- May have cytoprotective and gut-motility effects
- Synergistic with GHRH analogs
Potential Side Effects
- Pronounced hunger shortly after dosing
- Water retention and tingling
- Cortisol and prolactin elevation at higher doses
- Flushing or head-rush
Common Dosing
Research protocols cite ~100-300 mcg per dose, 1-3 times daily, often paired with a GHRH analog. Educational reference only, not personal advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy
- Uncontrolled diabetes
- Pregnancy or breastfeeding
- Not approved for human therapeutic use
CJC-1295
A long-acting growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to produce more growth hormone. Often paired with a ghrelin mimetic for synergistic GH release.
Sermorelin
A GHRH analog comprising the first 29 amino acids of growth hormone releasing hormone, historically used to assess and stimulate pituitary GH output. A gentler, physiologic GH peptide.
- View
On the actions of the growth hormone-releasing hexapeptide, GHRP
1991
- View
Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity
1993
- View
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers
2013
- View
Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects
2017